行情

EDIT

EDIT

Editas Medicine
NASDAQ

实时行情|Nasdaq Last Sale

19.56
-0.42
-2.10%
已收盘, 17:01 04/03 EDT
开盘
20.17
昨收
19.98
最高
20.33
最低
18.95
成交量
53.77万
成交额
--
52周最高
34.37
52周最低
14.01
市值
10.73亿
市盈率(TTM)
-7.3195
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EDIT价格均价为35.86,最高价位55.00,最低价为28.00。

EPS

EDIT 新闻

更多
  • Is CRISPR Therapeutics Stock a Buy?
  • MotleyFool.com · 21小时前
  • Better Buy: Editas Medicine vs Sangamo Therapeutics
  • MotleyFool.com · 4天前
  • Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
  • Zacks · 03/27 16:31
  • Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
  • Seeking Alpha - Article · 03/25 14:02

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

EDIT 简况

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
展开

微牛提供Editas Medicine Inc(NASDAQ-EDIT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EDIT股票新闻,以帮助您做出投资决策。